<DOC>
	<DOCNO>NCT00343785</DOCNO>
	<brief_summary>This clinical trial study well give cyclophosphamide together anti-thymocyte globulin follow methotrexate cyclosporine work prevent chronic graft-vs-host disease ( GVHD ) patient severe aplastic anemia undergo donor bone marrow transplant . Giving low dos chemotherapy , cyclophosphamide , donor bone marrow transplant help stop growth abnormal cell . It also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune system help destroy remain abnormal cell . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving anti-thymocyte globulin methotrexate cyclosporine transplant may stop happen</brief_summary>
	<brief_title>Cyclophosphamide Anti-thymocyte Globulin Followed By Methotrexate Cyclosporine Preventing Chronic Graft-Versus-Host Disease Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Minimize incidence chronic GVHD restricting transplant marrow dose 2.0-2.5 x 10^8 nucleated cells/kg . SECONDARY OBJECTIVES : I. Engraftment overall survival . OUTLINE : CONDITIONING REGIMEN : Patients receive cyclophosphamide intravenously ( IV ) day -5 -2 anti-thymocyte globulin IV 4-10 hour day -4 -2 . TRANSPLANTATION : Patients undergo allogeneic bone marrow transplantation day 0 . GVHD PROPHYLAXIS : Patients receive methotrexate IV day 1 , 3 , 6 , 11 cyclosporine IV 1 hour orally ( PO ) twice daily day -1 50 , follow taper 6 month graft . After completion study treatment , patient follow day 180 , 1 year , 1.5 year , 2 year , 3 year , yearly thereafter .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Any patient aplastic anemia marrow failure involve 2 three follow criterion : granulocyte &lt; 500/uL ; correct reticulocyte count &lt; 1 % ; platelet count &lt; 20,000/uL Availability human leukocyte antigen ( HLA ) match family member DONOR : Family member HLAmatched DONOR : If one HLAmatched family member available , priority give donor genotypically HLAidentical , appropriate cytomegalovirus ( CMV ) serology , ABO compatible , , case female donor , nonparous Severe disease aplastic anemia would severely limit probability survival graft procedure : Patients develop clonal cytogenetic abnormality myelodysplastic syndrome ( preleukemia ) Patients Fanconi 's anemia Aplasia secondary radiation cytotoxic chemotherapy Patients paroxysmal nocturnal hemoglobinuria develop aplastic anemia Severe organ toxicity : Cardiac insufficiency require treatment symptomatic coronary artery disease ; Severe hypoxemia , partial pressure oxygen ( pO2 ) &lt; 70 mm Hg , decrease diffusion capacity carbon monoxide ( DLCO ) &lt; 70 % predict ; mild hypoxemia , pO2 &lt; 80 mm Hg severely decrease DLCO &lt; 60 % predict ; Impaired renal function ( creatinine &gt; 2 time upper limit normal estimate creatinine clearance &lt; 60 ml/min ) Fungal infection radiological progression receipt amphotericin B active triazole great 1 month Human immunodeficiency virus ( HIV ) positive patient Females pregnant breastfeed DONOR : Donors increase anesthetic risk able psychologically medically tolerate procedure DONOR : HIVpositive donor</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>